FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
Avadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal"
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION ( EU ...
Avadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal" - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , Alkermes ( NASDAQ:ALKS )
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , Alkermes ( NASDAQ:ALKS )
Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share. The deal consideration includes $21 per share in cash and a non-transferable contingent value right ( CVR ) of potential additional cash payments of ...
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Halper Sadeh LLC Encourages TRUE, AVDL, GES Shareholders to Contact the Firm to Discuss Their Rights - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , Guess ( NYSE:GES )
NEW YORK, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Avadel Receives Unsolicited Proposal from Lundbeck
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION ( EU ...
Avadel Receives Unsolicited Proposal from Lundbeck - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , Alkermes ( NASDAQ:ALKS )
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study - Alkermes ( NASDAQ:ALKS )
Alkermes plc ( NASDAQ:ALKS ) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton ( formerly ALKS 2680 ) in narcolepsy type 2 ( NT2 ) .
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
ALKS or ILMN: Which Is the Better Value Stock Right Now?
ALKS vs. ILMN: Which Stock Is the Better Value Option?
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Applied Optoelectronics ( NASDAQ:AAOI ) , Alkermes ( NASDAQ:ALKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
Does Alkermes ( ALKS ) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?
The consensus price target hints at a 36.3% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Is Alkermes ( ALKS ) Stock Outpacing Its Medical Peers This Year?
Here is how Alkermes (ALKS) and Cardinal Health (CAH) have performed compared to their sector so far this year.
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut
PRGO beats Q3 earnings estimates but misses on sales. It also trims the 2025 outlook and launches a strategic review of its infant formula unit.
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales
Bausch Health's Q3 results top expectations as strong Salix and Solta sales fuel growth. Shares gain.
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth. 2025 guidance raised after strong demand.
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.
Alkermes ( ALKS ) Surpasses Q3 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +16.67% and +10.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , Jazz Pharmaceuticals ( NASDAQ:JAZZ ) , Alkermes ( NASDAQ:ALKS )
On Wednesday, Alkermes plc ( NASDAQ:ALKS ) agreed to acquire Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avadel Pharmaceuticals plc ( Nasdaq - AVDL ) , Middlefield Banc Corp. ( Nasdaq - MBCN ) , Heidrick & Struggles International, Inc. ( Nasdaq - HSII ) , Comerica Incorporated ( NYSE - CMA )
BALA CYNWYD, Pa., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
ALKS vs. RGEN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Alkermes ( ALKS Quick QuoteALKS - ) or Repligen ( RGEN Quick QuoteRGEN - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Wall Street Analysts Predict a 34.8% Upside in Alkermes ( ALKS ) : Here's What You Should Know
The mean of analysts' price targets for Alkermes (ALKS) points to a 34.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging Alkermes ( ALKS ) This Year?
Here is how Alkermes (ALKS) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Is Alkermes ( ALKS ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Do Options Traders Know Something About Alkermes Stock We Don't?
Investors need to pay close attention to ALKS stock based on the movements in the options market lately.
Agiloft and Spaulding Ridge Partner to Transform Contracting for CFOs and Global Enterprises
Strategic alliance to deliver enterprise-ready CLM transformation services to agility, compliance, and growth REDWOOD CITY, Calif., Sept. 29, 2025 /PRNewswire/ -- Agiloft, a leader in data-first contract lifecycle management ( CLM ) , today announced a strategic partnership with Spaulding Ridge, ...
This Ciena Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Ciena ( NYSE:CIEN ) , Alkermes ( NASDAQ:ALKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Global Psychotic Disorders Market Poised For Significant Growth
The global market for medications addressing psychotic disorders is projected to reach $32.1 billion by 2033, exhibiting a robust compound annual growth rate ( CAGR ) of 6.5% over the forecast period.
Immunovant ( IMVT ) Up 7.8% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Krystal Biotech ( KRYS ) Up 8.5% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday - Cogent Biosciences ( NASDAQ:COGT ) , Alkermes ( NASDAQ:ALKS )
U.S. stocks were mixed, with the Dow Jones index falling over 150 points on Wednesday. Shares of Macy's, Inc. M rose sharply during Wednesday's session after the company reported second-quarter results above estimates and raised its FY2025 guidance.
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Archrock ( NYSE:AROC ) , Alkermes ( NASDAQ:ALKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Compass Point analyst Ed Engel initiated coverage on Bullish BLSH with a Neutral rating and ...
